Antibiotic Therapy for Cystic Fibrosis
Introduction to Antibiotic Therapy
- The Cystic Fibrosis Foundation concludes that there is insufficient evidence to recommend monotherapy as equivalent to combination therapy for Pseudomonas aeruginosa infections during acute exacerbations 1
- The traditional rationale for combination therapy includes enhanced antimicrobial activity and theoretical reduction in resistance selection, though clinical outcomes data comparing approaches remain limited 1
- Insufficient data supports single antibiotic equivalence to multi-drug regimens for P. aeruginosa treatment during acute pulmonary exacerbations 1
Non-Tuberculous Mycobacteria Infections
- Monotherapy is explicitly contraindicated for all NTM infections in CF patients 2, 3, 4, 5
- The CF Foundation and ECFS recommend that monotherapy with a macrolide or other antimicrobial should never be used in treating M. abscessus complex pulmonary disease (100% consensus) 2, 3, 4
- Monotherapy with a macrolide or other antimicrobial agent should never be used for MAC pulmonary disease (100% consensus) 2, 3, 4, 5
- If a CF patient on chronic azithromycin develops a positive NTM culture, immediately discontinue azithromycin until NTM disease is ruled out, as monotherapy rapidly induces macrolide resistance 2, 4
Clinical Considerations
- Do not assume in vitro susceptibility testing predicts clinical outcomes in chronic CF infections 1
- Avoid single-agent therapy for acute P. aeruginosa exacerbations despite limited toxicity benefits, as insufficient evidence supports equivalence to combination therapy 1
- Never use azithromycin monotherapy for NTM infections - this rapidly induces resistance and is contraindicated with 100% consensus 2, 3, 4, 5
Antibiotic Selection for Cystic Fibrosis Patients
Chronic Maintenance Therapy
- The American Thoracic Society recommends inhaled tobramycin for moderate to severe disease (FEV1 <70% predicted) in patients ≥6 years with persistent P. aeruginosa to improve lung function, quality of life, and reduce exacerbations 6
- The American Thoracic Society recommends chronic oral azithromycin for patients ≥6 years with persistent P. aeruginosa to improve lung function and reduce exacerbations 6
- Dornase alfa (inhaled DNase) is strongly recommended for moderate-severe disease and recommended for mild disease 6
- Hypertonic saline 7% is recommended for patients ≥6 years to improve lung function and reduce exacerbations 6
Treatment of Non-Tuberculous Mycobacteria
- The American Thoracic Society recommends daily oral triple therapy for MAC pulmonary disease, including azithromycin 250-500 mg daily, rifampin 450-600 mg daily, and ethambutol 15 mg/kg daily 7, 8
- The CF Foundation explicitly recommends against intermittent (three times weekly) therapy in CF patients with MAC 7, 9
Key Clinical Recommendations
- The American College of Chest Physicians recommends combination IV antibiotics (typically an antipseudomonal beta-lactam plus an aminoglycoside) for P. aeruginosa exacerbations 10, 11
- The American Thoracic Society recommends continuing chronic maintenance therapies (inhaled tobramycin, dornase alfa, hypertonic saline) during acute exacerbations 11